Key Points
- 10x Genomics CEO Serge Saxonov sold 5,000 shares on April 14 at $24.56 for $122,800, leaving him with 1,167,273 shares (a 0.43% reduction in his position).
- He also sold 5,000 shares on March 24, 10,000 on March 23 and 9,632 on February 23 — 29,632 shares sold recently for about $590,663, signaling a pattern of insider selling.
- 10x Genomics (TXG) is trading near $25.24 with a $3.22 billion market cap; analysts’ consensus rating is Hold with an average price target of $19.46.
10x Genomics (NASDAQ:TXG - Get Free Report) CEO Serge Saxonov sold 5,000 shares of the company's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $24.56, for a total transaction of $122,800.00. Following the sale, the chief executive officer directly owned 1,167,273 shares of the company's stock, valued at $28,668,224.88. The trade was a 0.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Serge Saxonov also recently made the following trade(s):
- On Tuesday, March 24th, Serge Saxonov sold 5,000 shares of 10x Genomics stock. The stock was sold at an average price of $19.52, for a total transaction of $97,600.00.
- On Monday, March 23rd, Serge Saxonov sold 10,000 shares of 10x Genomics stock. The stock was sold at an average price of $19.13, for a total transaction of $191,300.00.
- On Monday, February 23rd, Serge Saxonov sold 9,632 shares of 10x Genomics stock. The stock was sold at an average price of $18.58, for a total transaction of $178,962.56.
10x Genomics Trading Down 0.4%
10x Genomics stock opened at $25.24 on Friday. The firm has a 50 day moving average of $20.54 and a 200 day moving average of $17.91. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -72.11 and a beta of 2.17. 10x Genomics has a 12-month low of $7.25 and a 12-month high of $25.69.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. The company had revenue of $166.03 million during the quarter, compared to analyst estimates of $160.35 million. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.89%. The firm's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) EPS. On average, analysts predict that 10x Genomics will post -1.43 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TXG. Geneos Wealth Management Inc. bought a new position in 10x Genomics in the 4th quarter worth approximately $38,000. Larson Financial Group LLC boosted its stake in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company's stock worth $39,000 after purchasing an additional 1,470 shares during the period. True Wealth Design LLC boosted its stake in 10x Genomics by 26.4% in the 3rd quarter. True Wealth Design LLC now owns 4,534 shares of the company's stock worth $53,000 after purchasing an additional 948 shares during the period. Abich Financial Wealth Management LLC bought a new position in 10x Genomics in the 3rd quarter worth approximately $56,000. Finally, Van ECK Associates Corp boosted its stake in 10x Genomics by 85.9% in the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company's stock worth $60,000 after purchasing an additional 1,695 shares during the period. 84.68% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. UBS Group increased their target price on shares of 10x Genomics from $14.00 to $20.00 and gave the stock a "neutral" rating in a report on Friday, February 20th. Barclays increased their target price on shares of 10x Genomics from $22.00 to $30.00 and gave the stock an "overweight" rating in a report on Tuesday. Stifel Nicolaus increased their target price on shares of 10x Genomics from $20.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Citigroup increased their target price on shares of 10x Genomics from $18.00 to $24.00 and gave the stock a "neutral" rating in a report on Tuesday, April 7th. Finally, Leerink Partners reduced their target price on shares of 10x Genomics from $22.00 to $20.00 and set a "market perform" rating for the company in a report on Tuesday, January 27th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $19.46.
Get Our Latest Research Report on 10x Genomics
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
